In this episode, Joe interviews Elliot Marseille, DrPH, MPP: founding director of UC Berkeley’s Collaborative for the Economics of Psychedelics (CEP), a network of health economists and researchers analyzing the economics behind emerging psychedelic-assisted therapies. In the early days of drug research, efficacy was the leading factor in decision making, but as time has gone […]

The post The Economics of Psychedelics appeared first on Psychedelics Today.

Previous articlePα+ Psychedelic Patent Analysis: April 2024
Next articleWhat to Expect: FDA Advisory Committee Set to Review MDMA-Assisted Therapy for PTSD